advertisement
Abstract #19136 Published in IGR 3-1
Intraocular pressure-lowering efficacy of latanoprost in patients with normal-tension glaucoma or primary open-angle glaucoma
Tamada Y; Taniguchi T; Murase H; Yamamoto T; Kitazawa YJournal of Ocular Pharmacology and Therapeutics 2001; 17: 19-25
The authors investigated the intraocular pressure (IOP)-lowering potential of latanoprost in patients with normal-tension glaucoma (NTG) or primary open-angle glaucoma (POAG). This prospective study included 59 NTG and 20 POAG patients treated with the following four dosing regimens of latanoprost: patients on no previous medication received latanoprost as initial therapy (Group I, n = 31); patients on beta-blocker therapy received latanoprost as adjunctive therapy (Group II, n = 9); patients on unoprostone monotherapy were switched to latanoprost monotherapy (Group III, n = 14); and patients previously on dual therapy with isopropyl unoprostone and beta-blocker were switched to a combined treatment of latanoprost and beta-blocker (Group IV, n = 25). IOP significantly decreased eight weeks after initiation of latanoprost therapy by 19.9% in Group I, 20.5% in Group II, 16.6% in Group III, and 12.2% in Group IV. In Groups I and II, there was a significant positive correlation between the magnitude of IOP reduction induced by latanoprost and the IOP level before latanoprost therapy. The IOP level before latanoprost therapy is a contributing factor in the IOP-lowering efficacy of latanoprost. Latanoprost is more effective in lowering IOP than isopropyl unoprostone.
Dr. T. Taniguchi, Department of Ophthalmology, Gifu University School of Medicine, 40 Tsukasa-machi, Gifu-shi, Gifu 500-8705, Japan
Classification:
11.4 Prostaglandins (Part of: 11 Medical treatment)
